Testosterone MDL Judge Refuses to Disturb Defense Verdict in Bellwether Case



DOCUMENTS
  • Order


CHICAGO — The judge overseeing the testosterone replacement therapy MDL docket has refused to order a new trial following a defense verdict in a bellwether case targeting Actavis Inc.’s Androderm, ruling that the drug maker’s failure to produce an FDA letter did not violate the court’s discovery order.

In an Aug. 6 order, Judge Matthew F. Kennelly of the U.S. District Court for the Northern District of Illinois further ruled that the court did not err in allowing Actavis to introduce the label of a drug the plaintiff was taking in conjunction with Androderm.

Minnesota resident Brad Martin alleges Androderm, …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: The Current Mass Tort Landscape - Best Management Practices & Updates on Key Litigation

September 28, 2022 - St. Louis, MO
Four Seasons Hotel, St. Louis

MORE DETAILS



HarrisMartin’s Webinar Series: Acetaminophen ASD/ADHD Product Liability Litigation

October 21, 2022

MORE DETAILS